Preface x
Acknowledgements xii
Notes on using *The Maudsley Prescribing Guidelines in Psychiatry* xiii
List of abbreviations xv

**Part 1  Drug treatment of major psychiatric conditions**  1

**Chapter 1  Schizophrenia and related psychoses**  3

ANTIPSYCHOTIC DRUGS  3
General introduction  3
General principles of prescribing  8
Minimum effective doses  9
Licensed maximum doses  12
Equivalent doses  14
High-dose antipsychotics: prescribing and monitoring  16
Combined antipsychotics  20
Antipsychotic prophylaxis  25
Negative symptoms  31
Monitoring  36
Relative adverse effects – a rough guide  39
Treatment algorithms for schizophrenia  40
First-generation antipsychotics – place in therapy  44
NICE guidelines for the treatment of schizophrenia  46
Antipsychotic response – to increase the dose, to switch, to add or just wait – what is the right move?  49
Acutely disturbed or violent behaviour  54
Antipsychotic depots/long-acting injections (LAs)  66
Depot/LAI antipsychotics – pharmacokinetics  71
Management of patients on long-term depots/LAs  73
Aripiprazole long-acting injection  75
Olanzapine long-acting injection  77
Paliperidone palmitate long-acting injection  79
Risperidone long-acting injection  82
Electroconvulsive therapy and psychosis 86
Omega-3 fatty acid (fish oils) in schizophrenia 88
ANTIPSYCHOTIC ADVERSE EFFECTS 90
Extrapyramidal symptoms 90
Akathisia 94
Weight gain 97
Treatment of antipsychotic-induced weight gain 99
Neuroleptic malignant syndrome 104
Catatonia 107
ECG changes – QT prolongation 112
Effect of antipsychotic medications on plasma lipids 119
Diabetes and impaired glucose tolerance 123
Blood pressure changes 130
Hyponatraemia 134
Hyperprolactinaemia 137
Sexual dysfunction 141
Pneumonia 148
Switching antipsychotics 150
Venous thromboembolism 153
REFRACTORY SCHIZOPHRENIA AND CLOZAPINE 156
Clozapine initiation schedule 156
Optimising clozapine treatment 158
Alternatives to clozapine 162
Re-starting clozapine after a break in treatment 169
Initiation of clozapine for community-based patients 170
CLOZAPINE ADVERSE EFFECTS 175
Clozapine: common adverse effects 175
Clozapine: uncommon or unusual adverse effects 179
Clozapine: serious haematological and cardiovascular adverse effects 184
Clozapine-induced hypersalivation 189
Clozapine-induced gastrointestinal hypomotility (CIGH) 193
Clozapine, neutropenia and lithium 197
Clozapine and chemotherapy 202

Chapter 2  Bipolar disorder 205
Lithium 205
Valproate 214
Carbamazepine 221
Antipsychotic drugs in bipolar disorder 226
Antipsychotic long-acting injections in bipolar disorder 229
Physical monitoring for people with bipolar disorder 232
Treatment of acute mania or hypomania 235
Rapid-cycling bipolar disorder 241
Bipolar depression 243
Prophylaxis in bipolar disorder 250
## Chapter 3  Depression and anxiety disorders

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression: introduction</td>
<td>255</td>
</tr>
<tr>
<td>Basic principles of prescribing in depression</td>
<td>255</td>
</tr>
<tr>
<td>Official guidance on the treatment of depression</td>
<td>256</td>
</tr>
<tr>
<td>Antidepressants: general overview</td>
<td>257</td>
</tr>
<tr>
<td>Recognised minimum effective doses of antidepressants</td>
<td>262</td>
</tr>
<tr>
<td>Drug treatment of depression</td>
<td>264</td>
</tr>
<tr>
<td>Treatment of refractory depression: first choice</td>
<td>267</td>
</tr>
<tr>
<td>Treatment of refractory depression: second choice</td>
<td>271</td>
</tr>
<tr>
<td>Treatment of refractory depression: other reported treatments</td>
<td>274</td>
</tr>
<tr>
<td>Psychotic depression</td>
<td>278</td>
</tr>
<tr>
<td>Electroconvulsive therapy and psychotropic drugs</td>
<td>281</td>
</tr>
<tr>
<td>Stimulants in depression</td>
<td>285</td>
</tr>
<tr>
<td>Post-stroke depression</td>
<td>290</td>
</tr>
<tr>
<td>Treatment of depression in the elderly</td>
<td>293</td>
</tr>
<tr>
<td>Antidepressants: alternative routes of administration</td>
<td>298</td>
</tr>
<tr>
<td>Antidepressant prophylaxis</td>
<td>306</td>
</tr>
<tr>
<td>Antidepressant discontinuation symptoms</td>
<td>310</td>
</tr>
<tr>
<td>Antidepressants: swapping and stopping</td>
<td>314</td>
</tr>
<tr>
<td>Drug interactions with antidepressants</td>
<td>321</td>
</tr>
<tr>
<td>Cardiac effects of antidepressants</td>
<td>325</td>
</tr>
<tr>
<td>Antidepressant-induced arrhythmia</td>
<td>329</td>
</tr>
<tr>
<td>Antidepressant-induced hyponatraemia</td>
<td>333</td>
</tr>
<tr>
<td>Antidepressants and hyperprolactinaemia</td>
<td>337</td>
</tr>
<tr>
<td>Antidepressants and diabetes mellitus</td>
<td>340</td>
</tr>
<tr>
<td>Antidepressants and sexual dysfunction</td>
<td>343</td>
</tr>
<tr>
<td>SSRIs and bleeding</td>
<td>347</td>
</tr>
<tr>
<td>St John’s wort</td>
<td>355</td>
</tr>
<tr>
<td>Antidepressants: relative adverse effects – a rough guide</td>
<td>358</td>
</tr>
<tr>
<td>Anxiety spectrum disorders</td>
<td>360</td>
</tr>
<tr>
<td>Benzodiazepines in the treatment of psychiatric disorders</td>
<td>373</td>
</tr>
<tr>
<td>Benzodiazepines: dependence and detoxification</td>
<td>377</td>
</tr>
<tr>
<td>Benzodiazepines and disinhibition</td>
<td>381</td>
</tr>
</tbody>
</table>

## Chapter 4  Addictions and substance misuse

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>385</td>
</tr>
<tr>
<td>Alcohol dependence</td>
<td>387</td>
</tr>
<tr>
<td>Opioid dependence</td>
<td>405</td>
</tr>
<tr>
<td>Nicotine and smoking cessation</td>
<td>431</td>
</tr>
<tr>
<td>Pharmacological treatment of dependence on stimulants</td>
<td>439</td>
</tr>
<tr>
<td>GHB and GBL dependence</td>
<td>442</td>
</tr>
<tr>
<td>Benzodiazepine misuse</td>
<td>445</td>
</tr>
<tr>
<td>Synthetic cannabinoid receptor agonists (SCRAs)</td>
<td>447</td>
</tr>
<tr>
<td>Interactions between ‘street drugs’ and prescribed psychotropic drugs</td>
<td>450</td>
</tr>
<tr>
<td>Drugs of misuse – a summary</td>
<td>454</td>
</tr>
</tbody>
</table>
Part 2  Drug treatment of special patient groups 459

Chapter 5  Children and adolescents 461
Principles of prescribing practice in childhood and adolescence 461
Depression in children and adolescents 463
Bipolar illness in children and adolescents 471
Psychosis in children and adolescents 478
Anxiety disorders in children and adolescents 480
Obsessive compulsive disorder (OCD) in children and adolescents 485
Post-traumatic stress disorder in children and adolescents 491
Attention deficit hyperactivity disorder 496
Autism spectrum disorder 504
Tics and Tourette's syndrome 512
Melatonin in the treatment of insomnia in children and adolescents 517
Rapid tranquillisation (RT) in children and adolescents 521
Doses of commonly used psychotropic drugs in children and adolescents 524

Chapter 6  Prescribing in older people 525
General principles 525
Dementia 529
Safer prescribing for physical conditions in dementia 557
Management of behavioural and psychological symptoms of dementia 570
A guide to medication doses of commonly used psychotropic drugs in older adults 586
Covert administration of medicines within food and drink 593

Chapter 7  Pregnancy and breastfeeding 599
Drug choice in pregnancy 599
Breastfeeding 619

Chapter 8  Hepatic and renal impairment 635
Hepatic impairment 635
Renal impairment 645

Part 3  Prescribing in specialist conditions 661

Chapter 9  Drug treatment of other psychiatric conditions 663
Borderline personality disorder 663
Eating disorders 667
Delirium 672
## Chapter 10  Drug treatment of psychiatric symptoms occurring in the context of other disorders 679

- General principles of prescribing in human immunodeficiency virus (HIV) 679
- Prescribing psychotropics in HIV 685
- Epilepsy 688
- 22q11.2 Deletion syndrome 696
- Learning disabilities 699
- Huntington’s disease 704
- Multiple sclerosis 709
- Parkinson’s disease 715
- Atrial fibrillation 719
- Bariatric surgery 722

## Part 4  Other aspects of psychotropic drug use 729

### Chapter 11  Pharmacokinetics 731

- Plasma level monitoring of psychotropic drugs 731
- Interpreting post-mortem blood concentrations 742
- Acting on clozapine plasma concentration results 744
- Psychotropic drugs and cytochrome (CYP) function 746
- Smoking and psychotropic drugs 750
- Drug interactions with alcohol 753

### Chapter 12  Other substances 759

- Caffeine 759
- Nicotine 765

### Chapter 13  Psychotropic drugs in special conditions 769

- Psychotropic drugs in overdose 769
- Driving and psychotropic drugs 776
- Psychotropic drugs and surgery 781

### Chapter 14  Miscellany 787

- Enhancing medication adherence 787
- Re-starting psychotropic medications after a period of non-compliance 794
- Biochemical and haematological effects of psychotropic medications 798
- Summary of psychiatric adverse effects of non-psychotropic medications 808
- Prescribing drugs outside their licensed indications ('off-label' prescribing) 813
- The Mental Health Act in England and Wales 816
- Site of administration of intramuscular injections 821

Index 825